Oral Cancer Cases to Increase 11 Percent This Year
February 13 2007 - 1:38PM
PR Newswire (US)
PHOENIX, Feb. 13 /PRNewswire-FirstCall/ -- Zila, Inc. (NASDAQ:ZILA)
noted with dismay that while the American Cancer Society (ACS)
celebrated new data with a headline "Cancer Deaths Down for Second
Year", the same data showed a marked increase in the number of
expected new cases and deaths due to oral cancer. "The ACS data,
published in 'Cancer Facts & Figures 2007', projects 34,360 new
cases of Oral Cavity & Pharynx Cancer - a remarkable 11 percent
increase over the 30,990 cases that ACS projected for 2006, and a
20 percent increase among males," notes Frank Bellizzi, president
of Zila Pharmaceuticals, Inc., marketer of the ViziLite(R) Plus
with TBlue630 system for the early detection of oral abnormalities
that could lead to cancer. Nearly as many women will be diagnosed
with oral cancer as with cervical cancer this year. ACS projects
that total deaths due to oral cancer will rise nearly two percent
to 7,550 in 2007, from 7,430 in 2006. "As the ACS celebrates a
decline in many cancers," Dr. Bellizzi added, "it is critical to
note that oral cancer remains a common cancer type in men, and a
critical threat to women. Early detection is the key to reducing
death and minimizing the quality-of-life impact of this insidious
disease. As the ACS reports, the 5-year survival rate when oral
cancer is detected early is 81.3 percent, but late detection
results in a survival rate of only 26 percent. "Dentists across
America are moving rapidly to adopt the three-minute, non-invasive,
absolutely painless ViziLite Plus technology to improve their
chances of detecting potentially deadly abnormal tissue at a very
early, highly treatable stage. Respected dental groups, like
Heartland Dental Care, Coast Dental, Aspen Dental, Midwest Dental
and SmileCare, as well as thousands of independent dental offices,
are now routinely providing ViziLite Plus exams as part of their
annual patient wellness evaluations. Major insurers are moving
quickly to extend coverage to this important technology." One
American dies every hour of oral cancer, and while tobacco and
alcohol use contribute to incidence, one quarter of all oral cancer
cases occur in people with no risk behaviors. "Take the ACS data to
heart," Dr. Bellizzi said. "Ask your dentist for an oral cancer
exam at your earliest opportunity." About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is a leading cancer diagnostic company
focused on oral cancer: - Zila Pharmaceuticals is dedicated to
establishing ViziLite(R) Plus as the new standard of care for the
early detection of oral abnormalities that could lead to cancer,
with initial focus on the dental market through Pro-Dentec(R), a
leading designer, manufacturer and marketer of products sold
exclusively to dental professionals for Soft Tissue Management
("STM(R)") including the Rota-dent(R) Professional Powered Brush,
the Pro-Select3(R) Piezo-Ultrasonic Scaler System and a suite of
pharmaceutical STM(R) products for both in-office and home-care
use. - Zila Biotechnology is focused on achieving regulatory
approval for the next generation oral cancer diagnostic,
OraTest(R), followed by the development of additional applications
of its cancer detection technologies. For more information about
Zila, visit http://www.zila.com/. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. The Company makes no
commitment, and disclaims any duty, to update or revise any
forward-looking statements to reflect future events or changes in
expectations. For a more detailed description of these and other
cautionary factors that may affect Zila's future results, please
refer to Zila's Form 10-K for its fiscal year ended July 31, 2006
and subsequent filings we make with the Securities and Exchange
Commission. DATASOURCE: Zila, Inc. CONTACT: Bill Sklar,
+1-520-299-2830, , for Zila, Inc. Web site: http://www.zila.com/
Copyright
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024